一、个人简历

马宗辉，中国药科大学药物化学博士，美国德克萨斯大学医学部博士后，中国农业科学院上海兽医研究所所聘研究员，入选上海市海外高层次人才计划。长期从事小分子创新药物的研究与开发，涵盖药物设计、合成、药效学评价、成药性优化及制备工艺研究。在《Molecular Cell》《Journal of Medicinal Chemistry》《European Journal of Medicinal Chemistry》《Bioorganic Chemistry》《PLOS Pathogens》等国际高水平SCI期刊发表论文20余篇。担任Med. Res. Rev.、J. Med. Chem、Eur. J. Med. Chem.等药物化学顶级期刊审稿人。作为主要发明人，获国家发明专利授权2项。参与研发的3款药物已进入临床研究阶段，并成功实现转化。

二、联系方式

办公电话：021-34293396

邮   箱：mazonghui@shvri.ac.cn

三、代表论著

1. Kumar, N.#; Ma, Z.#; Long, F.#; Bonam, S. R.; Lai, H. T.; Wu, S. Y.; Chen, H.; Hazell, N. C.; Bei, J.; Liu, X.; Chen, Y.; Wei, Z.; Chiang, C. M.; Zhou, J.; Hu, H. Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. PLoS Pathog. 2026, 22, e1013449.（共同第一作者）

2. Ma, Z.; Zhou, M.; Chen, H.; Shen, Q.; Zhou, J. Deubiquitinase-targeting chimeras (DUBTACs) as a potential paradigm-shifting drug discovery approach. J. Med. Chem. 2025, 68, 6897-6915.

3. Ma, Z.; Zhou, J. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders. J. Med. Chem. 2025, 68, 14129-14136.

4. Ma, Z.; Shen, Q.; Zhou, J.; Rezatapopt (PC14586): A First-in-Class Small Molecule p53 Y220C Mutant Protein Stabilizer in Clinical Trials. J. Med. Chem. 2025, 68, 6847-6849.

5. Ma, Z.; McAninch, S.; Liu, Z.; Zhang, C.; Chen, H.; He, J.; Yang, W.; Panganiban, R. P.; Cong, Y.; Yochum, G.; Brasier, A. R.; Pinchuk, I. V.; Tian, B.; Zhou, J. Orally bioavailable BRD4 BD1 inhibitor ZL0516 effectively suppresses colonic inflammation in animal models of inflammatory bowel disease. ACS Pharmacol. Transl. Sci. 2025, 8, 1152-1167.

6. Skibba, M.#; Ma, Z.#; Wilson, C. L.; Liu, Z.; Chen, H.; Tian, B.; Harr, T. J.; Schnapp, L. M.; Sandbo, N.; Zhou, J.; Brasier, A. R. An orally bioavailable BRD4 inhibitor disrupts expansion of a pathogenic epithelial-mesenchymal niche in bleomycin-induced fibrosis. Respir. Res. 2025, 26, 221.（共同第一作者）

7. Ma, Z.; Bolinger, A. A.; Chen, H.; Zhou, J. Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2). J. Med. Chem. 2023, 66, 10991-11026.

8. Ma, Z.; Jiang, L.; Li, B.; Liang, D.; Feng, Y.; Liu, L.; Jiang, C. Discovery of benzimidazole derivatives as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. Bioorg. Med. Chem. 2021, 46, 116352.

9. Ma, Z.; Jiang, L.; Li, G.; Liang, D.; Li, L.; Liu, L.; Jiang, C. Design, synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. Bioorg. Chem. 2020, 101, 103971.

10. Ma. Z.; Gao. G.; Fang, K.; Sun, H. Development of Novel Anticancer Agents with a Scaffold of Tetrahydropyrido[4,3-d]pyrimidine-2,4-dione. ACS Med. Chem. Lett. 2019, 10, 191-195.